SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

  P. Sarafidis ¹ AuthorId : 11250835
Author

  C. J. Ferro ² AuthorId : 11545726
Author

  E. Morales ³ AuthorId : 214251
Author

  A. Ortiz ⁴ AuthorId : 42328
Author

  J. Malyszko ⁵ AuthorId : 11393111
Author

  R. Hojs ⁶ AuthorId : 11545727
Author

  K. Khazim ⁷ AuthorId : 11545728
Author

  R. Ekart ⁶ AuthorId : 11545729
Author

  J. Valdivielso ⁸ AuthorId : 11545730
Author

  D. Fouque ^{9, 10, 11} AuthorId : 442811
Author

  G. M. London ¹² AuthorId : 11252375
Author

  Z. Massy ^{13, 14} AuthorId : 11167263
Author

  P. Ruggenenti ¹⁵ AuthorId : 11545731
Author

  E. Porrini ^{16, 17} AuthorId : 11545732
Author

  A. Wiecek ¹⁸ AuthorId : 11250841
Author

  C. Zoccali ¹⁹ AuthorId : 11250833
Author